Editas Medicine Inc (8EM F) stock market data APIs
€1.8843
0(0%)
as of March 30, 2026
Try our APIs with
free plan!
Editas Medicine Inc Financial Data Overview
Price chart is built with
Anychart
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Prev. Close
1.8843
Open
1.8843
High
1.8843
Low
1.8843
52 wk Range
0.8272-3.823
Market Cap
194 M
Shares Outstanding
97 872 K
Revenue
40 520 K
Beta
2.189
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Editas Medicine Inc data using free add-ons & libraries
Get Editas Medicine Inc Fundamental Data
Editas Medicine Inc Fundamental data includes:
- Net Revenue: 40 520 K
- EBITDA: -94 059 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-03-11
- EPS/Forecast: -0.21
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Editas Medicine Inc News
New
Editas Medicine (NASDAQ:EDIT) shareholders have endured a 87% loss from investing in the stock three years ago
Editas Medicine, Inc. (NASDAQ:EDIT) shareholders should be happy to see the share price up 24% in the last quarter. But the last three years have seen a terrible decline. In that time the share price ...
7 Mighty Healthcare Stocks Changing the Game of Medicine
With so many question marks facing the viability of the equities sector, concerned investors may want to turn their attention to compelling healthcare stocks. Primarily, the sector benefits from perma...
3 Stocks to Buy in the Booming Field of Gene Editing
The promise of gene editing is moving closer to being a reality. If you’re an investor with a speculative appetite and appropriate risk tolerance, you may want to consider a long position in gene e...
Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference
Editas Medicine, Inc. Anticipated 2024 milestones include: present reni-cel clinical data updates mid-year and year-end, initiate the RUBY clinical trial adolescent cohort, establish in vivo preclini...
Get Editas Medicine Inc fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
